KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech (KRYS) announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response (measured using RECIST v1.1 criteria) of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung ...